Key result
Tirzepatide fails to significantly reduce MACE but lowers all-cause mortality in type 2 diabetes.
Why the study?
Although tirzepatide is established for improving metabolic parameters in type 2 diabetes and obesity, its overall effects on major adverse cardiovascular events and all-cause mortality remain uncertain despite rapidly expanding clinical use.
Does tirzepatide reduce major adverse cardiovascular events (MACE) and all-cause mortality in adults with type 2 diabetes compared with placebo or active glucose-lowering therapies?
Meta-Analysis (n=24,177)
Does tirzepatide reduce major adverse cardiovascular events (MACE) and all-cause mortality in adults with type 2 diabetes compared with placebo or active glucose-lowering therapies?
In a meta-analysis of 13 RCTs involving 24,177 adults with type 2 diabetes, tirzepatide significantly reduced all-cause mortality by 16% compared with control therapies, though the reduction in MACE did not reach statistical significance.
Background The efficacy of tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, in improving metabolic parameters is well established in patients with type 2 diabetes and obesity. However, despite its rapidly expanding clinical use, the overall cardiovascular effects of tirzepatide remain uncertain. Purpose To assess the effects of tirzepatide on major adverse cardiovascular events (MACE) and all-cause mortality in adults with type 2 diabetes. Methods We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing tirzepatide with placebo or active glucose-lowering therapies in adults with type 2 diabetes. PubMed, Embase, and the Cochrane Library were systematically searched for RCTs published from inception to February 2026. Event counts were extracted from published reports, risk ratios (RRs) with 95% confidence intervals (CIs) were calculated and pooled using a random-effects model. Statistical analyses were performed using Review manager software version 10.0.1. Results We included 13 RCTs comprising 24,177 patients. Overall, 13,912 participants (57.5%) received tirzepatide, whereas the remaining participants received placebo (3.2%), long-acting insulin (9.5%), or GLP-1 receptor agonists (29.8%). There was no statistically significant difference between groups in MACE (RR 0.92; 95% CI 0.84–1.00; p=0.05; I²=0%; Figure 1). In contrast, tirzepatide was associated with a significant reduction in all-cause mortality (RR 0.84; 95% CI 0.76–0.93; p=0.0007; I²=0%; Figure 2). Conclusions In this meta-analysis of RCTs, tirzepatide was associated with a significant reduction in all-cause mortality in adults with type 2 diabetes compared with control therapies. No statistically significant difference was observed in MACE.Figure 1.MACEFigure2.All-cause mortality
No takes yet. Share an insight, caveat, or question.
Saffi et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus (n=24,177). Tirzepatide vs. Placebo, long-acting insulin, or GLP-1 receptor agonists was evaluated on Major adverse cardiovascular events (MACE) (RR 0.92, 95% CI 0.84-1.00, p=0.05). Tirzepatide showed no significant difference in MACE (RR 0.92; 95% CI 0.84-1.00; p=0.05) but reduced all-cause mortality (RR 0.84; 95% CI 0.76-0.93; p=0.0007) in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: